Military Central Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arriens, Cristina G
NCT05559671: Safety of the Herpes Zoster Subunit Vaccine in Lupus

Recruiting
4
224
US
Herpes Zoster Subunit (HZ/su) Vaccine, SHINGRIX, Placebo
NYU Langone Health
Systemic Lupus Erythematosus
01/27
01/27
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Terminated
3
275
Europe, Canada, Japan, US, RoW
secukinumab, AIN457
Novartis Pharmaceuticals
Lupus Nephritis
09/23
09/23
NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Recruiting
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
NAIVE, NCT04726553: Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

Recruiting
1
20
US
Anifrolumab, Medi 546, Standard of Care, azathioprine, methotrexate, mycophenolate mofetil, corticosteroids, antimalarials
Oklahoma Medical Research Foundation, NYU Langone Health, Yale University, Piedmont Heart Institute, Inc., Atlanta, GA, Columbia University
Systemic Lupus Erythematosus (SLE)
12/23
12/24
Mascio, Heather
NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Recruiting
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
Sirken, Gary
NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Recruiting
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26

Download Options